1. Immunology/Inflammation
  2. PD-1/PD-L1
  3. Acasunlimab

Acasunlimab  (Synonyms: GEN1046)

Cat. No.: HY-P99419 Purity: 99.90%
COA

Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer.

For research use only. We do not sell to patients.

CAS No. : 2253937-12-9

Size Price Stock Quantity
1 mg USD 750 In-stock
5 mg USD 1950 In-stock
10 mg USD 3120 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer[1][2].

Isotype

Ig(G1-kappa_G1-lambda2)

Species

Humanized

In Vitro

Acasunlimab (GEN1046; 0.001-1 μM; 0-525 min) promotes interactions between dendritic cells and T cells and enhances T-cell activation[1].
Acasunlimab (0.001-1 μM; 48 h; PD-L1+ Tumor Cells) induces dose-dependent, conditional T-cell proliferation and cytokine production and enhances antigen-specific T-cell–mediated cytotoxicity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Acasunlimab (GEN1046; 5 mg/kg; twice weekly for three cycles) has antitumor activity and inhibits tumor growth in double knock-in (dKI) transgenic C57BL/6 mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Double knock-in (dKI) transgenic C57BL/6 mice[1]
Dosage: 5 mg/kg
Administration: Intravenous injection; twice weekly for three cycles
Result: Had antitumor activity in double knock-in (dKI) transgenic C57BL/6 mice.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Acasunlimab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Ig(G1-kappa_G1-lambda2)
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Acasunlimab
Cat. No.:
HY-P99419
Quantity:
MCE Japan Authorized Agent: